miRagen Therapeutics Inc Initiated with a Buy at Wedbush

By Carrie Williams

miRagen Therapeutics Inc (NASDAQ: MGEN) received a Buy rating and a $19 price target from Wedbush analyst Liana Moussatos on February 21. The company’s shares closed yesterday at $14.05.

According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 10.2% and a 43.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Lexicon Pharmaceuticals.

miRagen Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $19.

The company has a one year high of $15.00 and a one year low of $10.60. Currently, miRagen Therapeutics Inc has an average volume of 57.82K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MGEN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Signal Genetics, Inc. is a commercial stage, molecular diagnostic company. It provides innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company was founded in January 2010 and is headquartered in Carlsbad, CA.